Minerva Neurosciences Inc shares jumped after a biotech clinical trial of a drug similar to its new drug, MIN-301, improved Parkinson’s disease symptoms in non-human Primates.
Minerva plans human clinical trials shortly.
Dr. Rémy Luthringer, Ph.D., president and CEO of Minerva said, “We believe MIN-301 and other peptides from our neuregulin platform may represent the next generation of therapies with neuroprotective activities in Parkinson’s and other neurodegenerative disorders.”
